Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.53 |
| ▸ | HTR2A | P28223 | 6/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7273672 | 0.88 | HTR2A (0.58) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL29473870 | 0.88 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL1047458 | 0.88 | TAAR1 (0.69) | TAAR1HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL26096716 | 0.86 | TAAR1 (0.67) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL34463042 | 0.86 | TAAR1 (0.66) | TAAR1HTR2AHTR2CADRA1AHTR2B | |
| SCHEMBL20562467 | 0.86 | TAAR1 (0.66) | TAAR1HTR2AHTR2CADRA1AHTR2B | |
| SCHEMBL584610 | 0.79 | TNKS2 (0.45) | HTR2B | |
| SCHEMBL11919300 | 0.79 | TAAR1 (0.47) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL585104 | 0.78 | ALDH1A1 (0.38) | TAAR1 | |
| SCHEMBL28154665 | 0.78 | HTR2B (0.43) | HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | YUHAN CORPORATION (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | YUHAN CORPORATION (KR) | 2019-05-16 | — | — | US | disclosed |
| EP-3483149-A1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Yuhan Corporation (KR) | 2019-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | ILK, SBDS, BDKRB1 | TAAR1 3745/4885HTR2A 4659/4885HTR2C 4702/4885 |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | ILK, SBDS, BDKRB1 | TAAR1 3745/4885HTR2A 4659/4885HTR2C 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.